Blood disorders
Lymphoma
淋巴瘤
A general term for a range of tumours of the lymphoid tissue.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 199
- cities
- 62
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 21% of the world's English-language research papers on lymphoma, 2021–2025 (13% in 2016–2020), and 19% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
199 hospitals in 62 cities
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 5 papers or 1 trial on lymphoma, or was a site in 9 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens lymphoma in that city. 52 more cities are in the menu below.
- 145 papers led
- 142 papers led
- 97 papers led
- 85 papers led
- 83 papers led
- 83 papers led
- 81 papers led
- 74 papers led
- 67 papers led
- 65 papers led
- 56 papers led
- 52 papers ledNo open trial led
- 48 papers led
- 46 papers led
- 43 papers led
- 37 papers led
- 36 papers ledNo open trial led
- 36 papers led
- 35 papers led
- 35 papers led
- 34 papers led
- 34 papers led
- 33 papers led
- 31 papers led
- 30 papers ledNo open trial led
- 29 papers led
- 27 papers led
- 27 papers ledNo open trial led
- 26 papers ledNo open trial led
- 26 papers ledNo open trial led
- 25 papers led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 25 papers ledNo open trial led
- 24 papers led
- 24 papers led
- 23 papers ledNo open trial led
- 23 papers led
- 22 papers ledNo open trial led
- 22 papers led
- 21 papers ledNo open trial led
- 21 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 19 papers ledNo open trial led
- 18 papers led
- 17 papers ledNo open trial led
- 16 papers led
- 16 papers ledNo open trial led
- 16 papers ledNo open trial led
- 15 papers led
- 15 papers ledNo open trial led
- 15 papers led
- 15 papers ledNo open trial led
- 15 papers led
- 14 papers led
- 14 papers ledNo open trial led
- 14 papers ledNo open trial led
- 14 papers led
- 14 papers led
- 13 papers led
- 13 papers led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers led
- 12 papers ledNo open trial led
- 12 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers led
- 11 papers ledNo open trial led
- 11 papers led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 10 papers led
- 10 papers ledNo open trial led
- 10 papers led
- 10 papers ledNo open trial led
- 10 papers led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers led
- 8 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers led
- 4 papers led
- 4 papers ledNo open trial led
- 4 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers led
- 1 paper led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
No listed hospital matches these filters.
By university or health system 59
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 201 papers led5 hospitals
- 178 papers led6 hospitals
- 176 papers led6 hospitals
- 174 papers led6 hospitals
- 150 papers led4 hospitals
- 147 papers led6 hospitals
- 131 papers led6 hospitals
- 130 papers led6 hospitals
- 121 papers led6 hospitals
- 115 papers led6 hospitals
- 115 papers led6 hospitals
- 82 papers led6 hospitals
- 77 papers led6 hospitals
- 72 papers led6 hospitals
- 68 papers led5 hospitals
- 52 papers led6 hospitals
- 46 papers led4 hospitals
- 44 papers led4 hospitals
- 44 papers led4 hospitals
- 44 papers led6 hospitals
- 42 papers led6 hospitals
- 41 papers led6 hospitals
- 40 papers led4 hospitals
- 40 papers led5 hospitals
- 37 papers led1 hospital
- 36 papers led6 hospitals
- 31 papers led4 hospitals
- 31 papers led3 hospitals
- 31 papers led2 hospitals
- 29 papers led5 hospitals
- 27 papers led4 hospitals
- 26 papers led3 hospitals
- 25 papers led1 hospital
- 24 papers led3 hospitals
- 24 papers led1 hospital
- 24 papers led6 hospitals
- 23 papers led3 hospitals
- 22 papers led3 hospitals
- 20 papers led1 hospital
- 20 papers led6 hospitals
- 18 papers led6 hospitals
- 18 papers led3 hospitals
- 16 papers led1 hospital
- 15 papers led2 hospitals
- 13 papers led6 hospitals
- 13 papers led1 hospital
- 13 papers led3 hospitals
- 12 papers led1 hospital
- 10 papers led5 hospitals
- 8 papers led1 hospital
- 8 papers led5 hospitals
- 7 papers led1 hospital
- 6 papers led1 hospital
- 5 papers led1 hospital
- 4 papers led1 hospital
- 3 papers led1 hospital
- 3 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
open trials on lymphoma in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with at least one listed hospital as lead sponsor or site. 406 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingSafety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2027-02
- Posted
- Registry
- NCT06902012
Age 18 years to Not stated (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingGB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT06875063
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingThe Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07039474
Age 18 years to 75 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingExploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07164560
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAnti CD19 Gene Therapy for B-cell Lymphoma
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07211048
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 4
- Started
- 2026-03
- Posted
- Registry
- NCT07218341
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou
- RecruitingGolidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07300514
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAn Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
- Phase
- Early phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07344818
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingU69-CART-Cells For R/R T-ALL
- Phase
- Phase 1
- Started
- 2026-10
- Posted
- Registry
- NCT07350863
Age 15 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingT Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07353840
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingZeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07372352
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingA Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07377578
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Nanning
- RecruitingPD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07380984
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingUnrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07381738
Age 14 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai
- RecruitingA Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
- Phase
- Phase 2/Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07389616
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingCRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07397832
Age 60 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingClinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2026-02
- Posted
- Registry
- NCT07398963
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingPD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07410520
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingGolidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07414758
Age 18 years to Not stated (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingThiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07416890
Age 18 years to 80 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingEfficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07418190
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07424833
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingExploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07441993
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou
- RecruitingPIC1 Injection Therapy for Relapsed/Refractory B-NHL
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07456371
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07481669
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingChidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07493109
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- RecruitingChidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07493148
Age 70 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- RecruitingCelecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07494565
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAssessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07496229
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengdu, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingGenetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07499271
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingTislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07502768
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingChidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07507318
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingThe Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07514169
Age 70 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07519772
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou
- RecruitingAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07523555
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingPomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07523737
Age 18 years to 75 years (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingCombination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07525466
Age 18 years to Not stated (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingCAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07538635
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingA Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
- Phase
- Early phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07548697
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingUltra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07554898
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer Hospital; 1 listed hospital as study siteHangzhou
- RecruitingMosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07555470
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07562022
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07570017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07570823
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07587840
Age 18 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingAn Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07598578
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingJL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07603479
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingR-PMDT Regimen in Newly Diagnosed PCNSL
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07604987
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07606937
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin
- RecruitingEfficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07608978
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07609823
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingA Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07609862
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingPhase I Study of FXS0683 in the Treatment of Blood Tumors
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07616089
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingSafety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07620314
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Phase I Study of JLM019 Injection
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07623850
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07628738
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Phase
- Phase 2/Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07634471
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingA Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07661537
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingBRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07678229
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingOrelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07680933
Age 18 years to 80 years (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- RecruitingOrelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07719556
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 1 listed hospital as study siteChangzhou, Nanjing
- RecruitingClinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07727083
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingHypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07749365
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingExploration of Circular RNA in B-cell Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07774572
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingIn Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07775508
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingOrelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07778212
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingCD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07779018
Age 18 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingCD38 Targeted -PET/ CT for Multiple Myeloma
- Phase
- N/A
- Started
- 2026-07
- Posted
- Registry
- NCT07782944
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Guilin Medical UniversityGuilin
- RecruitingA Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07788118
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07808827
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07823829
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesShanghai, Wuhan
- RecruitingZanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07839247
Age 70 years to Not stated (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingRegistry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07842835
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan
- RecruitingRapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07851363
Age 18 years to 75 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingStudy of JMBI-001 in Patients With MYC-Positive Advanced Cancers
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07864701
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingProspective ctDNA Testing in Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07878351
Age 18 years to Not stated (registered criteria)
Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing
- RecruitingBEX101 in B-cell Non-Hodgkin's Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07882641
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingEfficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
- Phase
- Phase 4
- Started
- 2026-10
- Posted
- Registry
- NCT07908888
Age 65 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingGN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-08
- Posted
- Registry
- NCT07910708
Age 18 years to 75 years (registered criteria)
Led by Pu'er People's HospitalPu'er
- RecruitingMultimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07941063
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingAn Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06487624
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Hangzhou, Yantai
- RecruitingGlofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06570447
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingOne Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06618313
Age 18 years to Not stated (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingA Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06642792
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06689917
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06697184
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Suzhou
- RecruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06717347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen
- RecruitingA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06742996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- RecruitingUB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06743503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin
- RecruitingPOLA-R-CHP in the First-line Treatment of Transformed DLBCL
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06743945
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingClinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06758037
Age 70 years to 100 years (registered criteria)
Led by First Affiliated Hospital of Ningbo UniversityNingbo
- RecruitingSafety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06758713
Age 18 years to 75 years (registered criteria)
Led by Third Affiliated Hospital of Southern Medical UniversityGuangzhou
- RecruitingSafety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06760039
Age 18 years to 80 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen University; 5 listed hospitals as study sitesBeijing, Fuzhou, Lanzhou, Nanchang, Zhanjiang, Zhuhai
- RecruitingCHiR Therapy for Elderly DLBCL Intolerant to Chemo
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06764017
Age 70 years to 100 years (registered criteria)
Led by First Affiliated Hospital of Ningbo UniversityNingbo
- RecruitingA Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06776952
Age 18 days to 70 days (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06792253
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingMZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06793189
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 2 listed hospitals as study sitesBeijing, Shanghai, Shenyang
- RecruitingEfficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06803693
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06820268
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shijiazhuang, Wuhan
- RecruitingA Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06822868
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingAxicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06826118
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingClinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06829771
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou
- RecruitingClinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06830031
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingRituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06832267
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingCAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06834529
Age 14 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingNovel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06838832
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingAcalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06846489
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingCD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT06850285
Age 15 years to 80 years (registered criteria)
Led by Shanxi Bethune HospitalTaiyuan
- RecruitingClinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06854445
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou
- RecruitingNewly-diagnosed Pediatric T-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06855810
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan
- RecruitingA Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06855823
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingHypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06867536
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingNanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06874946
Age 3 years to 70 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingStudy of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06883526
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06890065
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingComparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
- Phase
- Phase 2/Phase 3
- Started
- 2025-05
- Posted
- Registry
- NCT06895538
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingClinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06909474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06911502
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Jinan, Wuhan
- RecruitingA Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06914037
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingCD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06925464
Age 14 years to 70 years (registered criteria)
Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-05
- Posted
- Registry
- NCT06940960
Age 12 years to 75 years (registered criteria)
Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang
- RecruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06943872
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou
- RecruitingTucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT06947967
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingGT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06948981
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingVenetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT06958705
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingZanubrutinib Combined With G-CVP in Previously Untreated FL
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06959732
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingIntravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT06961669
Age 3 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingChimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06967038
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06973187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou
- RecruitingA Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
- Phase
- Early phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06976437
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Jiangsu UniversityChangzhou
- RecruitingEfficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06987916
Age 2 years to 75 years (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingBispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06996132
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT07000617
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing
- RecruitingEvaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07001540
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSelinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07002099
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingRGL-305+ Lymphoma + Exploratory Clinical Study
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT07006012
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingBCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07009002
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07011056
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingGlofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07012980
Age 70 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingOrelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT07022223
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou
- RecruitingCD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07022964
Age 14 years to 70 years (registered criteria)
Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai
- RecruitingA Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07053670
Age 18 years to 75 years (registered criteria)
Led by Tongji Hospital; 1 listed hospital as study siteShanghai, Wuhan
- RecruitingTislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07058103
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- RecruitingDZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07059650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingStudy on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT07070648
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT07072169
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingThe Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07073833
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai
- RecruitingCombination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT07074470
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingOrelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07078500
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingXinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
- Phase
- Phase 2/Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07084662
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingClinical Study of U01(ssCART-19) in Patients With B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT07093073
Age 2 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingTargeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Early phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07093411
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad Hospital; 3 listed hospitals as study sitesBeijing, Hefei, Xi'an, Xuzhou
- RecruitingGolidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07093710
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAn Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
- Phase
- Early phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07101705
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingClinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07106723
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07106749
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitinguCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07109518
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07124936
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingFixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07126678
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingGSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07138547
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07139873
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin
- RecruitingSupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07153068
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07154264
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- RecruitingVenetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07159620
Age 14 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingSafety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
- Phase
- Early phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07162012
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingZanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07165769
Age 18 years to 80 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingTislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07168317
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou
- RecruitingChemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
- Phase
- Phase 2/Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07168980
Age Not stated to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingOrelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07185373
Age 18 years to 75 years (registered criteria)
Led by Huashan Hospital; 11 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai, Xi'an, Zhengzhou
- RecruitingMetabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT07188077
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingPA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07188610
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA)
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07191431
Age 14 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingDrug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT07198230
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingAI-assisted Diagnosis of Malignant Brain Tumors
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07198256
Age 18 years to 100 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou
- RecruitingOrelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07199296
Age 14 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingAn Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07200375
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- Phase
- Early phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07205315
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingOrelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07208981
Age 18 years to 75 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingZanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07233720
Age not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingThe Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07240194
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingUniversal CAR-T Cell Therapy for NHL
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT07248163
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingAllo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07253129
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingPirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07255963
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingPomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
- Phase
- N/A
- Started
- 2025-08
- Posted
- Registry
- NCT07257510
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingMulticenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07259070
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingKSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07260812
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingObinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07261163
Age 18 years to 80 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingZanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
- Phase
- Phase 4
- Started
- 2025-11
- Posted
- Registry
- NCT07270835
Age 14 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingReal-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07270861
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingOrelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07272499
Age 14 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07283796
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingClinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07284927
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
- RecruitingZanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07299149
Age 18 years to 90 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingRandomised Controlled Trial of Artificial Intelligence-assisted Health Education
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT07305337
Age 18 years to 90 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingPolymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07321301
Age 14 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07350850
Age 18 years to Not stated (registered criteria)
Led by Tongji Hospital; 2 listed hospitals as study sitesChangchun, Fuzhou, Wuhan
- RecruitingApplication of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
- Phase
- Phase 4
- Started
- 2025-11
- Posted
- Registry
- NCT07355699
Age 18 years to Not stated (registered criteria)
Led by Beijing Tongren Hospital; 2 listed hospitals as study sitesBeijing, Shenyang
- RecruitingApplication of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07371923
Age 18 years to Not stated (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingOrelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07372365
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingA Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Early phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07376642
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Hangzhou
- RecruitingOrelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07448324
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingEBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07450391
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingGlofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07460362
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingT Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR
- Phase
- Not given
- Started
- 2025-10
- Posted
- Registry
- NCT07470996
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingEnhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07489989
Age 18 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingEfficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT07508605
Age 18 years to 75 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingGolidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07754890
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingLow-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
- Phase
- Not given
- Started
- 2025-08
- Posted
- Registry
- NCT07763054
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Central South UniversityHaikou
- RecruitingEfficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)
- Phase
- Phase 4
- Started
- 2025-10
- Posted
- Registry
- NCT07934537
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingThiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
- Phase
- Phase 1
- Started
- 2024-03
- Posted
- Registry
- NCT06060782
Age 18 years to 65 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingSHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-02
- Posted
- Registry
- NCT06122389
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAzacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06176027
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingTGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06206174
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06219356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou
- RecruitingOrelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06228963
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingGVM±R in Patients With Relapsed or Refractory Aggressive NHL.
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06244368
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingThe Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2024-03
- Posted
- Registry
- NCT06307600
Age 3 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan
- RecruitingA Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-03
- Posted
- Registry
- NCT06313957
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing, Zhengzhou
- RecruitingScreening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06314334
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Shanghai
- RecruitingAllogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06321289
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingTCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06323525
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingIntratumoral CAN2109 in Subjects With Solid Tumors
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06332430
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06341556
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingCD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
- Phase
- Early phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06346912
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
- Phase
- N/A
- Started
- 2024-02
- Posted
- Registry
- NCT06355739
Age 3 years to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingCAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06365671
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06375733
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanning, Zhengzhou
- RecruitingLinperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06376721
Age 18 years to 75 years (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06387121
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingChidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06393361
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingTargeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06395870
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteHefei, Tianjin
- RecruitingLinperlisib Combined With Chidamide in Patients With PTCL
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06421948
Age 18 years to 80 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06436677
Age 18 years to 75 years (registered criteria)
Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing
- RecruitingStudy Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06445517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Tianjin
- RecruitingCD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06445803
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanchang, Shanghai
- RecruitingA Cohort Study in Newly Diagnosed MZL
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06449885
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingOrelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06454968
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingSequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
- Phase
- Phase 1
- Started
- 2024-06
- Posted
- Registry
- NCT06464861
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06471738
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingProspective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
- Phase
- N/A
- Started
- 2024-06
- Posted
- Registry
- NCT06478472
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingCD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06479356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingGlofitamab in Chinese Patients With R/R DLBCL
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06481826
Age 18 years to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingStudy of AXT-1003 in Subjects With Advanced Malignant Tumors.
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06484985
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai
- RecruitingCMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06486337
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingLinperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06489808
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06494371
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingBendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06496308
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingZanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06503263
Age 14 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingOptimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06504940
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAn Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06517004
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSelinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06517511
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shanghai
- RecruitingExploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06519526
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingComparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06520163
Age 18 years to 75 years (registered criteria)
Led by Affiliated People's Hospital of Ningbo University; 3 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou
- RecruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06521255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou
- RecruitingThe Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06522555
Age 70 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingPI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06530550
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingRegistry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06534463
Age 14 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingMilaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06534762
Age 18 years to 65 years (registered criteria)
Led by Zhejiang Provincial People's HospitalHangzhou
- RecruitingDZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06539182
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing
- RecruitingCellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06541327
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingZanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06553352
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingA Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06554561
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06554600
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06556199
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingBrentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
- Phase
- Phase 2/Phase 3
- Started
- 2024-09
- Posted
- Registry
- NCT06563245
Age 2 years to 35 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06566586
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingOxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06566807
Age 18 years to Not stated (registered criteria)
Led by Huai'an First People's HospitalHuai'an
- RecruitingA Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06569485
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingLinperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06592170
Age 18 years to Not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingR-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06594640
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingBCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06598722
Age 18 years to 60 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingAxicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
- Phase
- Phase 4
- Started
- 2024-09
- Posted
- Registry
- NCT06609304
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingA Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06615193
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Suzhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingTargeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
- Phase
- Early phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06633341
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06634589
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFuzhou, Hangzhou, Suzhou, Wenzhou
- RecruitingOrelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06647940
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Lanzhou, Shantou, Zhuhai
- RecruitingLarge Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06651853
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingPola-ZR2P in Previously Untreated DLBCL
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06664411
Age 14 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingRLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06674096
Age 65 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingGlofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06682130
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingA Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06683885
Age 65 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingDemethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06686108
Age 14 years to 55 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingCD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06696846
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingOrelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06700798
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Nanchang UniversityNanchang
- RecruitingRadiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06704555
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingClinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06707259
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSafety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
- Phase
- Early phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06716164
Age 19 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingJAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06716658
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingRD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06732492
Age 3 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingPhase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06733051
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteBeijing, Guangzhou
- RecruitingA Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06734871
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingCD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06735495
Age 3 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingGolidocitinib Plus CHOP in Newly Diagnosed PTCL
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06739265
Age 18 years to 70 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingVHAG in Treating R/R T-ALL/LBL
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06742463
Age 14 years to 74 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06742502
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteFuzhou
- RecruitingPET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
- Phase
- Not given
- Started
- 2024-07
- Posted
- Registry
- NCT06755775
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingSintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06824883
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingSintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06848569
Age 1 year to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingCD70-targeted immunoPET Imaging of Malignant Cancers
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06852638
Age 18 years to 80 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingNanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06880913
Age 12 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingChidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06891157
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingThe Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06911710
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingA Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06971523
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingZR-MTX for PIOL Phase II Trial
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06973811
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingIntegrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT07059741
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingPomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT07072208
Age 70 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingBendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT07072221
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingChidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT07074457
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingValue of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT07155954
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingLinperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT07195799
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingPredictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
- Phase
- Not given
- Started
- 2024-02
- Posted
- Registry
- NCT07236203
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEfficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT07584889
Age 18 years to 75 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingPredictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma
- Phase
- N/A
- Started
- 2024-07
- Posted
- Registry
- NCT07657494
Age 18 years to Not stated (registered criteria)
Led by Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing
- RecruitingCombination of CAR-DC Vaccine and ICIs in Malignant Tumors
- Phase
- Phase 1
- Started
- 2023-07
- Posted
- Registry
- NCT05631886
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingGenotype-guided Treatment in Newly Diagnosed PTCL
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05675813
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCapizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
- Phase
- Phase 3
- Started
- 2023-02
- Posted
- Registry
- NCT05681260
Age 12 months to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai
- RecruitingSelinexor in Combination With MTX+Ritu to Treat R/R CNSL
- Phase
- Phase 1/Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT05698147
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Hefei, Shanghai, Zhengzhou
- RecruitingThe Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2023-04
- Posted
- Registry
- NCT05741359
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Wuhan
- RecruitingClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05768529
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Shanghai, Suzhou
- RecruitingA Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05800977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingA Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
- Phase
- Phase 1/Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05806099
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingSecondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
- Phase
- Phase 4
- Started
- 2023-05
- Posted
- Registry
- NCT05806580
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingFrontline of ASCT in High-risk DLBCL
- Phase
- Not given
- Started
- 2023-05
- Posted
- Registry
- NCT05831865
Age 18 years to 70 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingClinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-05
- Posted
- Registry
- NCT05833893
Age 14 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingStudy of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-01
- Posted
- Registry
- NCT05842707
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
- Phase
- Phase 1
- Started
- 2023-10
- Posted
- Registry
- NCT05892718
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingA Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT05899621
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05931263
Age 18 years to 65 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- RecruitingA Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05933967
Age 18 years to 70 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingCD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT05948033
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingPianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT05949931
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingChidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05958719
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingProspective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
- Phase
- Phase 2
- Started
- 2023-05
- Posted
- Registry
- NCT05976997
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingTRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06014073
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingReal-World Study of DLBCL With Different Genetic Subtypes
- Phase
- Not given
- Started
- 2023-10
- Posted
- Registry
- NCT06026488
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingPhase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2023-09
- Posted
- Registry
- NCT06047197
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06066203
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
- Phase
- N/A
- Started
- 2023-12
- Posted
- Registry
- NCT06069830
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06082102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT06084936
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou
- RecruitingA Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06090539
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Nanchang
- RecruitingSafety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
- Phase
- Early phase 1
- Started
- 2023-11
- Posted
- Registry
- NCT06120166
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Study of OR for Second-line Treatment of Refractory MZL
- Phase
- Phase 4
- Started
- 2023-01
- Posted
- Registry
- NCT06134284
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Ningbo
- RecruitingA Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06136351
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
- Phase
- Phase 1
- Started
- 2023-08
- Posted
- Registry
- NCT06136364
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06136559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou
- RecruitingLenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06151080
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingChidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06151106
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingChidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06158386
Age 18 years to Not stated; women only (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingAZA Combined With RCHOP in P53-mutated DLBCL.
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06158399
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingA Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06170489
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06176729
Age 70 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingClinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
- Phase
- Phase 1
- Started
- 2023-12
- Posted
- Registry
- NCT06180174
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAzacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06190067
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingRCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
- Phase
- N/A
- Started
- 2023-12
- Posted
- Registry
- NCT06190301
Age 18 years to 75 years (registered criteria)
Led by Zhongshan Ophthalmic CenterGuangzhou
- RecruitingThe Pathogenesis and Prognostic Factors of Lymphoma
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT06203652
Age not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingThe Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06503276
Age 18 years to 75 years (registered criteria)
Led by Shanghai Ninth People's HospitalShanghai
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2023-09
- Posted
- Registry
- NCT06678282
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingAn Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Phase
- Early phase 1
- Started
- 2023-12
- Posted
- Registry
- NCT06693973
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
- Phase
- Early phase 1
- Started
- 2023-09
- Posted
- Registry
- NCT06756321
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Nantong UniversityNantong
- RecruitingA Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
- Phase
- N/A
- Started
- 2023-12
- Posted
- Registry
- NCT06783816
Age not stated (registered criteria)
Led by Shanxi Bethune HospitalTaiyuan
- RecruitingRelma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06876688
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingEfficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT07097207
Age 18 years to 75 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingHigh-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
- Phase
- Not given
- Started
- 2023-09
- Posted
- Registry
- NCT07205523
Age not stated (registered criteria)
Led by Affiliated Hospital of Qinghai UniversityXining
- RecruitingCell Free DNA in Mature B-cell Lymphoma
- Phase
- Not given
- Started
- 2022-09
- Posted
- Registry
- NCT04088422
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Phase
- Phase 1
- Started
- 2022-03
- Posted
- Registry
- NCT05091424
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Nanchang, Tianjin
- RecruitingA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Phase
- Phase 2/Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05139017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase
- Phase 3
- Started
- 2022-07
- Posted
- Registry
- NCT05254743
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan
- RecruitingR-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
- Phase
- Phase 2
- Started
- 2022-02
- Posted
- Registry
- NCT05257018
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteUrumqi
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
- RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Phase
- Phase 1/Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05294731
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
- Phase
- Phase 1
- Started
- 2022-08
- Posted
- Registry
- NCT05341557
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesTianjin
- RecruitingClinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
- Phase
- Phase 1
- Started
- 2022-07
- Posted
- Registry
- NCT05472558
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
- Phase
- Phase 1/Phase 2
- Started
- 2022-07
- Posted
- Registry
- NCT05487170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingA Real World Study of Ensartinib in Advanced ALK-positive NSCLC
- Phase
- Not given
- Started
- 2022-05
- Posted
- Registry
- NCT05498064
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT05506410
Age 18 years to 90 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingA Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
- Phase
- N/A
- Started
- 2022-09
- Posted
- Registry
- NCT05514327
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingTreAtments and outComes in paTients With prImary CutAneous Lymphoma
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT05518851
Age not stated (registered criteria)
Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Jinan
- RecruitingA Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
- Phase
- Phase 1
- Started
- 2022-05
- Posted
- Registry
- NCT05528055
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan
- RecruitingA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05533775
Age 6 months to 30 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Nanning
- RecruitingAllogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05554939
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingOrelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2022-08
- Posted
- Registry
- NCT05600660
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingThe Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
- Phase
- N/A
- Started
- 2022-09
- Posted
- Registry
- NCT05618041
Age 14 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTaiyuan
- RecruitingCD7 CAR-T Cells in T-cell Lymphoma/Leukemia
- Phase
- N/A
- Started
- 2022-10
- Posted
- Registry
- NCT05620680
Age 18 years to 75 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingA Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05623982
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Qingdao
- RecruitingClinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
- Phase
- N/A
- Started
- 2022-08
- Posted
- Registry
- NCT05626400
Age 2 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteLangfang
- RecruitingCD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
- Phase
- Phase 1
- Started
- 2022-12
- Posted
- Registry
- NCT05659628
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Ningbo
- RecruitingPediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2022-08
- Posted
- Registry
- NCT05660473
Age 14 years to 60 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingObinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05846750
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingObinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
- Phase
- Not given
- Started
- 2022-11
- Posted
- Registry
- NCT05846763
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingZR2 Sequential Immunochemotherapy for Newly Treated MCL
- Phase
- Phase 2
- Started
- 2022-08
- Posted
- Registry
- NCT05992597
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingZanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT06005870
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingCD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2022-01
- Posted
- Registry
- NCT06081478
Age 14 years to 85 years (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingStudy to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2022-07
- Posted
- Registry
- NCT06909877
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingRituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma
- Phase
- N/A
- Started
- 2022-12
- Posted
- Registry
- NCT06946407
Age Not stated to 60 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingHigh-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2022-01
- Posted
- Registry
- NCT07014943
Age 16 years to 70 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingCD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
- Phase
- Early phase 1
- Started
- 2021-11
- Posted
- Registry
- NCT04662294
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingRituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2021-01
- Posted
- Registry
- NCT04737889
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingEfficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04922567
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingOrelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2021-07
- Posted
- Registry
- NCT04961515
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingOrelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
- Phase
- Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT04989621
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou
- RecruitingA Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2021-07
- Posted
- Registry
- NCT04993690
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingFirst in Human, Dose Escalation Study of AN4005
- Phase
- Phase 1
- Started
- 2021-09
- Posted
- Registry
- NCT04999384
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Harbin, Wuhan
- RecruitingA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT05006716
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
- RecruitingThe Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
- Phase
- Phase 3
- Started
- 2021-09
- Posted
- Registry
- NCT05018520
Age 14 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingR-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
- Phase
- N/A
- Started
- 2021-08
- Posted
- Registry
- NCT05040555
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- RecruitingStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT05147467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesGuangzhou, Haikou, Hangzhou, Nanchang, Suzhou, Wuhan, Zhengzhou
- RecruitingOrelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT05209620
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingSafety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT06021678
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesJinan, Tianjin, Zhengzhou
- RecruitingA Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
- Phase
- Phase 1
- Started
- 2021-03
- Posted
- Registry
- NCT06189391
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou
- RecruitingA Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2021-10
- Posted
- Registry
- NCT06725524
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Started
- 2020-01
- Posted
- Registry
- NCT03936153
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Lanzhou, Linyi, Shanghai, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
- Phase
- Early phase 1
- Started
- 2020-01
- Posted
- Registry
- NCT04227015
Age 3 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
- Phase
- Phase 3
- Started
- 2020-05
- Posted
- Registry
- NCT04365036
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- RecruitingAssessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
- Phase
- Phase 1/Phase 2
- Started
- 2020-06
- Posted
- Registry
- NCT04440436
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 1/Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04494503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan
- RecruitingValue of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
- Phase
- Early phase 1
- Started
- 2020-08
- Posted
- Registry
- NCT04504526
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 2
- Started
- 2020-10
- Posted
- Registry
- NCT04586478
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou
- RecruitingNational Longitudinal Cohort of Hematological Diseases
- Phase
- Not given
- Started
- 2020-12
- Posted
- Registry
- NCT04645199
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2020-12
- Posted
- Registry
- NCT04661020
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingPhase Ib Clinical Study of Keynatinib
- Phase
- Phase 1
- Started
- 2020-09
- Posted
- Registry
- NCT04807881
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Chengdu, Shanghai
- RecruitingClinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2020-01
- Posted
- Registry
- NCT05182957
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingInternational Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Phase
- Phase 3
- Started
- 2019-08
- Posted
- Registry
- NCT04043494
Age Not stated to 18 years (registered criteria)
Led by University HospitalChangsha
- RecruitingBCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
- Phase
- Phase 1
- Started
- 2019-07
- Posted
- Registry
- NCT04162353
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen
- RecruitingCorrelation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT04263935
Age not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Phase
- Phase 1
- Started
- 2018-04
- Posted
- Registry
- NCT03460977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Nanjing, Wenzhou
- RecruitingA Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL
- Phase
- Not given
- Started
- 2018-03
- Posted
- Registry
- NCT03494296
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Harbin Medical UniversityHarbin
- RecruitingChina Lymphoma Patient Registry Study
- Phase
- Not given
- Started
- 2017-05
- Posted
- Registry
- NCT03313271
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
- Phase
- Not given
- Started
- 2016-10
- Posted
- Registry
- NCT02848274
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2014-10
- Posted
- Registry
- NCT02259556
Age 16 years to 80 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingOptimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
- Phase
- Not given
- Started
- 2013-06
- Posted
- Registry
- NCT06795113
Age 18 years to 100 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingEstablishing Prospective Mediastinal Tumor Database of PUMCH
- Phase
- Not given
- Started
- 2012-01
- Posted
- Registry
- NCT06421805
Age not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingTreatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
- Phase
- Phase 2/Phase 3
- Started
- 2010-09
- Posted
- Registry
- NCT02657785
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingTherapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
- Phase
- Phase 2/Phase 3
- Started
- 2010-09
- Posted
- Registry
- NCT02836158
Age 60 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingA Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
- Phase
- Phase 1
- Started
- 2026-08
- Posted
- Registry
- NCT06970496
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Nanchang, Shanghai, Wenzhou, Xi'an
- Not yet recruitingCAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
- Phase
- Early phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT06986434
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingGlofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07231250
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingClinical Study of XP-006 mRNA Vaccine for R/R B-NHL
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07334574
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingSHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07347288
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingIMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07355283
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingClinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07367685
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Fujian Medical UniversityQuanzhou
- Not yet recruitingLisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07398638
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingZillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07405255
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingEfficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07459608
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingReal-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07472621
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingHEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07483749
Age 1 year to 21 years (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- Not yet recruitingA Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07511114
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingU96-CAR-T-Cells For R/R B-ALL
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07511426
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingA Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07525817
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- Not yet recruitingAclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07535710
Age 60 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingAclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07535762
Age 65 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingEvaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07539610
Age 18 years to 69 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingSintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07542912
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingThe Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07548255
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingSelinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07554482
Age 18 years to 75 years (registered criteria)
Led by Beijing Tongren HospitalBeijing
- Not yet recruitingA Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07574528
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07583771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingA Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07585747
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesJinan, Nanchang, Shenzhen, Tianjin, Zhengzhou
- Not yet recruitingAI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07594899
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07599423
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingLisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07601607
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingLME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07602322
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingAI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric Lymphoma
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07609355
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingPomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07609446
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingRimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07613788
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingAdebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07615283
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingPirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07622784
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingPola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07638787
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingTR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07639879
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingRituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07654465
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07658352
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingGlofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase
- Not given
- Started
- 2026-06
- Posted
- Registry
- NCT07669194
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingGoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07670260
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingA Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07676175
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Xi'an
- Not yet recruitingOrelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07677813
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- Not yet recruitingLisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07684950
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingReal-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07695896
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingA Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07705308
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 2 listed hospitals as study sitesShanghai
- Not yet recruitingNew Genotype-guided Treatment in Newly Diagnosed PTCL
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07706959
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingBirelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
- Phase
- Phase 2/Phase 3
- Started
- 2026-09
- Posted
- Registry
- NCT07712588
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Chongqing, Harbin, Shanghai
- Not yet recruitingAI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07717177
Age 70 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingEfficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07717580
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- Not yet recruitingA Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07719855
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingPirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07744724
Age 18 years to 65 years (registered criteria)
Led by Changzhou No.2 People's Hospital; 1 listed hospital as study siteChangzhou, Nanjing
- Not yet recruitingPirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07744737
Age 18 years to 80 years (registered criteria)
Led by Changzhou No.2 People's Hospital; 1 listed hospital as study siteChangzhou, Nanjing
- Not yet recruitingPirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07744750
Age 18 years to Not stated (registered criteria)
Led by Changzhou No.2 People's Hospital; 1 listed hospital as study siteChangzhou, Nanjing
- Not yet recruitingThe Efficacy of CAPCT in Patients With PTCL
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07746245
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingGolidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07753642
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07758491
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingR-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07764601
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangzhou, Nanjing
- Not yet recruitingGELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07768943
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingSonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07774234
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingPirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07812493
Age 14 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07818499
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Suzhou
- Not yet recruitingSCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07819188
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingA Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07854639
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- Not yet recruitingA Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07855016
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- Not yet recruitingGlofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07888621
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingProphylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07917624
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingTafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-12
- Posted
- Registry
- NCT07938619
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingPirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure
- Phase
- Phase 2
- Started
- 2026-12
- Posted
- Registry
- NCT07944651
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingOrelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07945353
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingHigh-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06646211
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingThe Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT06747299
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingEfficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06757894
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingAZA Combined with R-GemOx for Elderly DLBCL Patients
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06778902
Age 60 years to 90 years (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- Not yet recruitingMechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06788600
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingEvaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06845241
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Nanchang, Tianjin, Zhengzhou
- Not yet recruitingThe Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT06863441
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06879470
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT06886139
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingZanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06890585
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingZanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06918015
Age 18 years to 80 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingBrentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT06925555
Age 18 years to 70 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingStudy to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT06935136
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingGlofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
- Phase
- Phase 4
- Started
- 2025-05
- Posted
- Registry
- NCT06956092
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingObinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06961500
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingBR Combined With OR in Treatment-naïve Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07008053
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 5 listed hospitals as study sitesChangsha, Fuzhou, Jinan, Qingdao, Shijiazhuang, Tianjin
- Not yet recruitingJWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07024147
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingA Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07032324
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingAssessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07032532
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07034508
Age 18 years to 80 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07035379
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingA Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07068906
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingRN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07113496
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingCD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07117305
Age 14 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingPirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07122609
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingHomoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07159906
Age 18 years to 99 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingNovel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
- Phase
- Early phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07168291
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- Not yet recruitingEvaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07187960
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou
- Not yet recruitingChemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07206264
Age 60 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 3 listed hospitals as study sitesFuzhou, Harbin, Jinan, Tianjin
- Not yet recruitingA Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
- Phase
- Phase 1
- Started
- 2025-11
- Posted
- Registry
- NCT07234045
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
- Phase
- Phase 4
- Started
- 2025-12
- Posted
- Registry
- NCT07264894
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingA Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07316907
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Jiangsu UniversityChangzhou
- Not yet recruitingA Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07316920
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Jiangsu UniversityChangzhou
- Not yet recruitingClinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07345741
Age 18 years to 78 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingA Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06255704
Age 18 years to 70 years (registered criteria)
Led by Shanxi Cancer HospitalTaiyuan
- Not yet recruitingThe Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-02
- Posted
- Registry
- NCT06255795
Age 14 years to 70 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingPlasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
- Phase
- N/A
- Started
- 2024-02
- Posted
- Registry
- NCT06289959
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingA First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06318884
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Zhengzhou
- Not yet recruitingLinperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06324994
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteDalian
- Not yet recruitingA Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06368167
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingZanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06549335
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingChidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06563778
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingJWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06567080
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingCAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06567366
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingMolecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06594432
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06646666
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingCAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06647329
Age 14 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingThe Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT06656234
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingPralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT06671717
Age 18 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingClinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma
- Phase
- N/A
- Started
- 2023-01
- Posted
- Registry
- NCT05681403
Age 18 years to 60 years (registered criteria)
Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an
- Not yet recruitingReal World Study of Linperlisib for Lymphoma Treatment
- Phase
- Not given
- Started
- 2023-05
- Posted
- Registry
- NCT05863871
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 1 listed hospital as study siteShanghai, Tianjin
- Not yet recruitingSafety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT05909098
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShiyan
- Not yet recruitingSelinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06062641
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingRelmacabtagene Autoleucel in Hematologic Malignancies
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT06142188
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingA Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma
- Phase
- N/A
- Started
- 2022-06
- Posted
- Registry
- NCT05343377
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Enrolling by invitationA Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2026-08
- Posted
- Registry
- NCT07784309
Age 3 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Enrolling by invitationCord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06827782
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Enrolling by invitationReal-world Study of Acalabrutinib
- Phase
- Not given
- Started
- 2024-07
- Posted
- Registry
- NCT06767891
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Enrolling by invitationA Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT07348575
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Nanchang UniversityNanchang
- Enrolling by invitationEfficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
- Phase
- Not given
- Started
- 2024-09
- Posted
- Registry
- NCT07450040
Age 18 years to 70 years (registered criteria)
Led by Eye & ENT Hospital of Fudan UniversityShanghai
- Enrolling by invitationAC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
- Phase
- Phase 3
- Started
- 2023-01
- Posted
- Registry
- NCT05678933
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 18 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.